Enveric Biosciences Issues Shareholder Letter Providing Strategic Vision

Propelling pipeline with normally happening and engineered mixes at first centeredaround the advancement of cannabinoids for drug use

Everyone has collected an exceptionally refined chief group, Board of Directors, and Scientific Advisory Board to control the Company through the administrative and clinical pathway

Organization assessing business improvement openings for extending IP portfolio and item pipeline to handle new signs for extra medicines

Enveric Biosciences, Inc. (NASDAQ: ENVB at https://www.webull.com/quote/nasdaq-envb) a patient-first biotechnology organization creating novel cannabinoid meds to improve personal satisfaction for disease patients, today gave an investor letter from its Chairman and CEO, David Johnson, reporting on the Company’s corporate activities and vision.

For the benefit of our leadership group and Board of Directors, I might want to offer our earnest thanks to you just for your steadfastness and backing all through the way toward finishing our Nasdaq posting, name change, and most as of late the end of our $10 million financings.

We accept that Enveric Biosciences is presently very much situated to execute its vision to broaden and improve personal satisfaction for disease patients deprived through exploring and creating novel steady consideration treatments that can add life to patients’ years, not only years to their lives.

Our group is attempting to propel our pipeline and accomplish this objective – at the same time tending to a huge neglected clinical need on the planet today. This procedure is planned to empower the clinical groups of oncologists and medical caretakers to help patients proceeding to experience the ill effects of disease therapies’ incapacitating results.

This is a huge market with next to zero late clinical development that we know about to address these strong consideration signs. Thus, patients are compelled to endure anguishing physical and mental results from the norm of care malignant growth medicines, for example, radiodermatitis, chemotherapy-instigated fringe neuropathy (CIPN), despondency, torment, and nervousness. These results sway treatment consistency and patient results, however, they likewise contrarily sway tolerant personal satisfaction.

To address this issue, NASDAQ ENVB’s central goal is to distinguish and create underestimated, under-investigated, novel solution exacerbates that are normally happening or engineered. Our broad information recommends that cannabinoid subsidiaries and other common dynamic mixes, including hallucinogenics, can be utilized across various conveyance techniques for these strong consideration signs to serve the patient, brain, and body.

The end of our new delicate trade toward the finish of December 2020 and financings were significant achievements, as we trust it situated us to all the more likely quicken our pipeline’s innovative work. In 2021, we plan to accomplish different achievements across a few signs with the authority and aptitude of our leadership group, Board of Directors, and Scientific Advisory Board.  You can check more other information like for nyse stic u at https://www.webull.com/quote/nyse-stic-u.